Figure 2From: BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal CarcinomaKaplan-Meier curves for DFS and OS of patients with BCL2L12 mRNA-positive and mRNA-negative nasopharyngeal tumors. BCL2L12 mRNA expression has an unfavorable prognostic value for nasopharyngeal carcinoma, since patients with BCL2L12 mRNA-positive nasopharyngeal tumors have significantly shorter DFS (P = 0.020) (A) and OS (P = 0.27) (B), compared with NPC patients with BCL2L12 mRNA-negative tumors.Back to article page